Coronavirus: Israeli Data Supports Effectiveness of Pfizer Vaccine – Maccabi

Less than 0.01% of people who received Pfizer’s COVID-19 vaccine contracted the virus more than a week after receiving the second dose, a leading Israeli healthcare provider said on Monday. Preliminary results shared by Israeli HMO Maccabi showed that only 20 people outside About 128,600 people who received both shots have since been infected with the COVID-19 virus. Israel is a world leader with its rapid vaccination, although the data also comes during a nationwide exclusion that helped stem the contagion. Israelites began receiving the first shots of Pfizer’s vaccine on December 19. The country provides Pfizer with weekly data updates on its vaccine campaign under a co-operation agreement that can help other countries adjust their own vaccinations. “According to Maccabi’s experts, this is preliminary data, but the numbers are very encouraging,” Maccabi said in a statement. “Maccabi reports that 50% of the 20 people infected are suffering from chronic diseases. disease with symptoms such as headache, cough, weakness or No one was hospitalized or had a fever above 38.5 C. Most patients tested on COVID-19 due to exposure to a verified patient, said Anat Ekka Zohar , director of Maccabi’s information and digital health division, said ‘the fact that the infected patients come from different profiles is consistent with Pfizer’s results.

“We will closely monitor these patients to see if they suffer from mild symptoms only and do not develop complications due to the virus,” she said. More than 2.6 million Israelis received a single dose of the vaccine and About 1.2 million received both shots, out of a population of about 9 million. Israel reported about 600,000 viral infections and 4,478 deaths during the pandemic.